December 2016 Current Affairs
7 DEC
NEWS
6 DEC
NEWS
5 DEC
NEWS
3 DEC
NEWS
2 DEC
NEWS
1 DEC
NEWS

November 2016 Current Affairs
30 NOV
NEWS
29 NOV
NEWS
28 NOV
NEWS
26 NOV
NEWS
25 NOV
NEWS
24 NOV
NEWS

October 2016 Current Affairs
31 OCT
NEWS
27 OCT
NEWS
26 OCT
NEWS
25 OCT
NEWS
24 OCT
NEWS
22 OCT
NEWS

September 2016 Current Affairs
30 SEP
NEWS
29 SEP
NEWS
28 SEP
NEWS
27 SEP
NEWS
26 SEP
NEWS
24 SEP
NEWS

August 2016 Current Affairs
31 AUG
NEWS
30 AUG
NEWS
29 AUG
NEWS
27 AUG
NEWS
26 AUG
NEWS
25 AUG
NEWS

Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets

Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets
09 July 2016 Current Affairs: Zydus Cadila, a leading global healthcare firm, on 7 July 2016 inked a non-exclusive, royalty free agreement with the Medicines Patent Pool (MPP). Under the pact they will be manufacturing global pharma major Bristol-Myers Squibb’s daclatasvir tablets used for the treatment of Hepatitis C Virus (HCV).

Bristol-Myers Squibb’s daclatasvir is a novel direct-acting antiviral (DAA) that is proven to help cure multiple genotypes of HCV.

The agreement sub-licences Zydus to produce and sell daclatasvir in 112 low and middle income countries. Between 130 and 150 million people worldwide are estimated to have HCV.

The MPP licence allows generic manufacturers to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Daclatasvir, in combination with other DAAs, for example sofosbuvir, produces high cure rates after 12 weeks of treatment, with recent Phase III studies demonstrating  that  the  regimen  could  cure  up  to  100%  of  HCV  patients  depending  on genotype and stage of liver disease.

Zydus Cadila : Zydus  Cadila  is  an  innovative,  global  pharmaceutical  company  that  discovers,  develops, manufactures and markets a broad range of healthcare therapies. The group launched its own patented NCE –Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

It also launched ‘Exemptia’ the world’s first biosimilar of Adalimumab for the treatment  of  inflammatory  arthritis,  Ulcerative  Colitis  and  Crohn’s  Disease  in  adult  & paediatric  patients.  The group aspires to be a research-based pharmaceutical company by 2020. The group employs over 19000 people worldwide.


December 2016 Current affairs
7 DEC
NEWS
6 DEC
NEWS
5 DEC
NEWS
3 DEC
NEWS
2 DEC
NEWS
1 DEC
NEWS

November 2016 Current affairs
30 NOV
NEWS
29 NOV
NEWS
28 NOV
NEWS
26 NOV
NEWS
25 NOV
NEWS
24 NOV
NEWS




October 2016 Current affairs
31 OCT
NEWS
27 OCT
NEWS
26 OCT
NEWS
25 OCT
NEWS
24 OCT
NEWS
22 OCT
NEWS

September 2016 Current affairs
30 SEP
NEWS
29 SEP
NEWS
28 SEP
NEWS
27 SEP
NEWS
26 SEP
NEWS
24 SEP
NEWS

August 2016 Current affairs
31 AUG
NEWS
30 AUG
NEWS
29 AUG
NEWS
27 AUG
NEWS
26 AUG
NEWS
25 AUG
NEWS



FreshersLive - No.1 Job site in India. Fresherslive Current Affairs 2016 section offers informative quiz questions with answers regarding latest current affairs today for all sorts of competitive exams like UPSC, TNPSC , IFS, IAS, IPS, railway exams (RRB) and banking exams like IPBS PO, IPBS clerk, Federal Bank PO, ICICI, SBI, RBI legal officer & Grade officer posts and much more. Register with us to get latest Current Affairs Updates. Also get latest Current Affairs news and quiz Updates for free alerts daily through E-mail

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.